Physiomics PLC (GB:PYC)
LSE:PYC
Top Page
Physiomics
(LSE:PYC)
Select Model
Select Model
Rating:48Neutral
Price Target:
0.45 p
▲(60.71% Upside)
Action:ReiteratedDate:03/12/26
The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.
Positive Factors
Revenue rebound in 2025
A strong 2025 revenue rebound (≈+51% vs 2024) signals recovering client demand and improving commercial traction. Sustained top-line growth can enable operating leverage, increase repeat-fee opportunities, and support scaling of project teams and multi-phase engagements over the next several quarters.
Negative Factors
Persistent cash burn
Operating and free cash flow were both materially negative in 2025 and the multi-year pattern shows recurring cash burn. Persistent outflows force reliance on external funding, dilute shareholders, constrain investment in people and tools, and raise execution risk if revenue momentum weakens.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound in 2025
A strong 2025 revenue rebound (≈+51% vs 2024) signals recovering client demand and improving commercial traction. Sustained top-line growth can enable operating leverage, increase repeat-fee opportunities, and support scaling of project teams and multi-phase engagements over the next several quarters.
Read all positive factors
Physiomics (PYC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.06M
Dividend YieldN/A
Average Volume (3M)2.43M
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth44.32%
EPS Growth60.00%
CountryUK
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding453,208,700
10 Day Avg. Volume1,168,038
30 Day Avg. Volume2,434,740
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.60
Price to Sales (P/S)1.41
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Physiomics Business Overview & Revenue Model
Company Description
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union. It offers modeling, simulation...
How the Company Makes Money
Physiomics primarily makes money by selling modelling and simulation work to external customers on a contract basis. The core revenue stream is fee-for-service project income, where clients (typically pharmaceutical and biotechnology companies and...
Physiomics Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 953.00K | 784.00K | 543.25K | 597.35K | 830.27K | 702.31K |
| Gross Profit | -543.08K | -435.08K | -677.43K | -581.62K | -429.01K | -365.79K |
| EBITDA | -553.33K | -448.21K | -659.80K | -561.57K | -347.84K | -324.52K |
| Net Income | -485.25K | -415.25K | -609.35K | -477.26K | -253.14K | -215.83K |
Balance Sheet | ||||||
| Total Assets | 558.00K | 892.03K | 422.60K | 674.39K | 1.12M | 1.32M |
| Cash, Cash Equivalents and Short-Term Investments | 257.00K | 461.24K | 191.07K | 416.59K | 687.67K | 1.04M |
| Total Debt | 0.00 | 0.00 | 3.83K | 7.35K | 0.00 | 0.00 |
| Total Liabilities | 165.00K | 199.85K | 140.08K | 142.67K | 140.61K | 157.57K |
| Stockholders Equity | 393.00K | 692.17K | 282.53K | 531.72K | 974.81K | 1.17M |
Cash Flow | ||||||
| Free Cash Flow | -469.08K | -550.08K | -565.44K | -271.50K | -358.62K | -48.65K |
| Operating Cash Flow | -464.14K | -546.14K | -548.13K | -264.86K | -349.25K | -32.50K |
| Investing Cash Flow | -4.41K | -3.41K | -15.21K | -6.22K | -9.37K | -16.15K |
| Financing Cash Flow | 456.73K | 819.73K | 337.83K | 0.00 | 2.85K | 44.24K |
Physiomics Technical Analysis
Positive
0.28
Price Trends
0.48
Negative
0.39
Positive
0.42
Positive
Market Momentum
>-0.01
Negative
50.13
Neutral
65.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PYC, the sentiment is Positive. The current price of 0.28 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.48, and below the 200-day MA of 0.42, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.13 is Neutral, neither overbought nor oversold. The STOCH value of 65.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:PYC.
Physiomics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £7.00M | -7.18 | -15.57% | ― | 13.32% | 55.07% | |
49 Neutral | £4.19M | -0.88 | -53.79% | ― | ― | 85.56% | |
48 Neutral | £2.06M | -0.72 | -89.43% | ― | 44.32% | 60.00% | |
43 Neutral | £5.42M | -2.61 | -2.42% | ― | ― | ― | |
41 Neutral | £2.15M | ― | ― | ― | 418.49% | 27.86% | |
40 Underperform | £8.58M | -0.25 | -316.67% | ― | 72.17% | 79.03% |
* Healthcare Sector Average
GB:PYC
Physiomics
0.46
0.07
16.67%
GB:TCF
Evgen Pharma
0.20
-0.02
-11.36%
GB:IXI
IXICO plc
7.55
-0.20
-2.58%
GB:OPTI
OptiBiotix Health
5.25
-10.25
-66.13%
GB:OBD
Oxford BioDynamics
0.20
-0.22
-52.38%
GB:VAL
ValiRx plc
0.29
-0.24
-44.76%
Physiomics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Physiomics Urges Shareholders to Reject Activist Board Shake-Up
Negative
Apr 8, 2026
Physiomics has urged shareholders to vote against resolutions proposed for a requisitioned general meeting on 29 April 2026, arguing that the activist-led bid to reshape the board is premature and could disrupt the company’s commercialisatio...
Executive/Board ChangesShareholder Meetings
Physiomics Board Urges Shareholders to Reject Investor-Led Board Overhaul
Negative
Apr 2, 2026
Physiomics has published a circular convening a requisitioned general meeting on 29 April 2026 after shareholder Michael Whitlow, who holds about 12.35% of the company, sought to overhaul the board by appointing three new directors and removing fo...
Private Placements and FinancingShareholder Meetings
Physiomics cancels general meeting after improving terms of equity placing
Positive
Mar 20, 2026
Physiomics has cancelled the general meeting that had been scheduled for 7 April 2026 after revising the terms of its previously announced equity fundraising. The board scrapped the original placing at 0.3 pence per share and instead completed, su...
Business Operations and StrategyPrivate Placements and Financing
Physiomics Raises £600,000 Via Retail Offer and Placing to Support Growth
Positive
Mar 18, 2026
Physiomics plc, a UK AIM-listed specialist in modelling, simulation and data-driven decision support for drug development and personalised medicine, provides computational tools and bespoke models that help streamline discovery, pre-clinical and c...
Business Operations and StrategyPrivate Placements and Financing
Physiomics launches revised WRAP retail offer alongside £490,000 placing
Neutral
Mar 17, 2026
Physiomics plc has launched a revised retail equity offer via Winterflood’s Retail Access Platform to raise up to £110,000 by issuing as many as 27.5 million new shares at £0.004, matching the price of a concurrent £490,000 in...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Physiomics Raises £490,000 in Revised Placing and Launches Retail Offer to Fund Growth
Positive
Mar 17, 2026
Physiomics has raised £490,000 through a discounted placing of 122.5 million new shares at £0.004 each and plans to launch a WRAP retail offer of up to a further £110,000 for existing shareholders on the same terms. The revised fund...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Physiomics Faces Shareholder Push for Full Board Overhaul
Negative
Mar 16, 2026
Physiomics plc has received a shareholder requisition to convene a general meeting seeking to overhaul its board, led by investor Michael Whitlow, who holds about 13.68% of the company’s share capital. The proposed resolutions would appoint ...
Private Placements and FinancingShareholder Meetings
Physiomics Raises £673k in Oversubscribed Retail and Placing Fundraise
Positive
Mar 13, 2026
Physiomics plc has completed an oversubscribed WRAP Retail Offer, raising gross proceeds of £223,279.48 through the issue of 74,426,493 new ordinary shares at the same price as a previously announced placing. Together, the retail offer and pl...
Private Placements and FinancingShareholder Meetings
Physiomics Opens Retail Share Offer Alongside Discounted Placing
Neutral
Mar 10, 2026
Physiomics plc has launched a Winterflood Retail Access Platform offer to raise up to £49,999.98 by issuing up to 16,666,660 new ordinary shares at £0.003 each, matching the price of a concurrent institutional placing of approximately &#...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Physiomics posts record half-year income as new Biometrics arm accelerates growth
Positive
Feb 16, 2026
Physiomics reported record first-half total income of £528,000 for the six months to 31 December 2025, up 51% year-on-year and its highest half-year income since inception, driven by expanded Modelling and Simulation work and a new Biometrics...
Business Operations and Strategy
Physiomics wins South Korean oncology modelling contract
Positive
Feb 12, 2026
Physiomics plc has secured a new contract with a South Korean clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates and immuno-oncology therapies for cancer. The project, worth up to £66,600, will see Ph...
Business Operations and Strategy
Physiomics Wins New Numab Therapeutics Contract to Model Key Immunology Asset
Positive
Jan 28, 2026
Physiomics plc has secured a new contract from long-standing client Numab Therapeutics AG to develop a pharmacokinetic-pharmacodynamic (PK/PD) model for a key asset in Numab’s immunology and inflammation pipeline, reinforcing its role as a s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.